NCT02938013View on ClinicalTrials.gov

deLIVER: Direct Acting Antiviral Effects on the Liver

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2020

Conditions
HCV CoinfectionLiver DiseaseHIV
Interventions
DRUG

Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]

antiviral therapy for HCV

DRUG

Sofosbuvir/Velpatasvir (SOF/VEL)

antiviral therapy for HCV

Trial Locations (1)

21287

Johns Hopkins Hospital : The John G. Bartlett Specialty Practice, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT02938013 - deLIVER: Direct Acting Antiviral Effects on the Liver | Biotech Hunter | Biotech Hunter